Procollagen type I (PC-I)

Procollagen type I is the triple-helical precursor molecule of Type I collagen, the primary structural component of the human extracellular matrix found predominantly in bone, skin, tendons, and ligaments [1, 8]. It is synthesized by fibroblasts and osteoblasts as a pro-peptide containing large N- and C-terminal propeptides that prevent premature fibril formation within the cell [9, 13]. Upon secretion into the extracellular space, these propeptides are enzymatically cleaved by specific proteinases, such as bone morphogenetic protein-1 (BMP-1), allowing the resulting tropocollagen to assemble into mature, high-tensile-strength fibrils [6, 16]. Pathologically, the dysregulation of procollagen type I leads to severe conditions: excessive deposition drives systemic fibrosis in the lungs, liver, and heart, while genetic mutations in the COL1A1 or COL1A2 genes result in structural defects such as Osteogenesis Imperfecta [4, 5, 14]. From a therapeutic perspective, procollagen I synthesis and its processing enzymes are key targets for antifibrotic agents like halofuginone and BMP-1 inhibitors [7, 17]. Furthermore, the cleaved N-terminal propeptide (PINP) is widely utilized as a gold-standard clinical biomarker for monitoring bone formation rates and assessing the efficacy of osteoporosis treatments [2, 3, 19].

Other names

Type I procollagenPro-alpha1(I) chainPro-alpha2(I) chainP1NP precursorPICP precursor

Inhibition of procollagen type I synthesis (e.g., via TGF-beta pathway modulation or specific inhibitors like halofuginone) [1, 17]; Inhibition of propeptide cleavage by procollagen C-proteinase/BMP-1 (e.g., UK-383,367) [7, 13]; Stimulation of synthesis via osteoblast anabolic activity (e.g., teriparatide) [2, 3]; Inhibition of post-translational modifications such as prolyl 4-hydroxylation [5, 8]; Reduction of systemic turnover via antiresorptive mechanisms [3, 10].